Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis

INTRODUCTION: Key clinical guidelines recommend anti-vascular endothelial growth factor (VEGF) therapy as first-line treatment for visual impairment due to diabetic macular oedema (DMO). A systematic literature review (SLR) and network meta-analysis (NMA) were conducted comparing the relative effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Sydnor, Shelby, Chatterjee, Swarnendu, Cooney, Philip, Kaur, Simarjeet, Macmillan, Tom, Stewart, Daisy, Munro, Isobel, Bandeiras, Cátia, Paine, Abby, Felizzi, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241757/
https://www.ncbi.nlm.nih.gov/pubmed/37198521
http://dx.doi.org/10.1007/s13300-023-01410-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241757/
https://www.ncbi.nlm.nih.gov/pubmed/37198521
http://dx.doi.org/10.1007/s13300-023-01410-8

Ejemplares similares